LGALS3 and type 2 diabetes mellitus: In contrast, in T2DM patients, higher levels of galectin-3 were associated with increased risk of developing the primary outcome (HR 1.57 (1.07–2.30), p = 0.022), along with a history of cerebrovascular events (HR 9.01 (2.10–38.7), p = 0.003).